AMDL's tumour marker in German trials:
This article was originally published in Clinica
Some 230 patients with the most prevalent types of cancer are being enrolled in a German trial of AMDL's DR-70 cancer test. The US company expects the trial, which is comparing the ELISA blood test with other cancer tests in clinical use in Germany, to be completed in the first quarter of 1996. Already available commercially in Canada, the DR-70 test will be marketed in Europe by AMDL's joint venture with Briana Bio-Tech, International Cancer Diagnostics.